文献速递头颈与中枢神经肿瘤

特瑞普利单抗治疗经治复发或转移性鼻咽癌的疗效、安全性及生物标志物:POLARIS-02 II期临床试验

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
PubMed 文献 · J Clin Oncol · 2021-01-25

POLARIS-02为单臂多中心II期研究,评估特瑞普利单抗3 mg/kg每2周治疗化疗难治性复发或转移性鼻咽癌。190例患者客观缓解率20.5%,中位缓解持续时间12.8个月,中位总生存17.4个月,安全性可控。血浆EBV DNA第28天下降≥50%与更好缓解相关。

要点

  • 特瑞普利单抗在化疗难治性鼻咽癌中ORR达20.5%,中位OS 17.4个月。
  • 血浆EBV DNA第28天下降≥50%者ORR显著更高(48.3% vs 5.7%)。

核心结论

  • 特瑞普利单抗在化疗难治性转移性鼻咽癌中具有可控的安全性和持久的临床缓解。
  • 血浆EBV DNA拷贝数早期下降与有利缓解相关。

研究设计与样本

  • 单臂、多中心II期临床研究(POLARIS-02)。
  • 纳入190例复发或转移性鼻咽癌患者,接受特瑞普利单抗3 mg/kg每2周静脉输注直至确认疾病进展或不可接受毒性。
  • 主要终点为客观缓解率,次要终点包括安全性、缓解持续时间、无进展生存期和总生存期。

主要发现

  • 全部190例患者ORR为20.5%,中位DOR 12.8个月,中位PFS 1.9个月,中位OS 17.4个月。
  • 92例至少二线系统化疗失败患者中ORR为23.9%。
  • 肿瘤突变负荷中位值0.95 muts/mega-base,对缓解无预测价值;174例全外显子测序显示11q13区域基因组扩增或ETV6基因组改变患者对特瑞普利单抗反应差。

关键数值与推荐

  • 特瑞普利单抗给药方案为3 mg/kg每2周静脉输注。
  • 肿瘤突变负荷中位值0.95 muts/mega-base。

临床怎么用

  • 特瑞普利单抗可作为化疗难治性复发或转移性鼻咽癌的治疗选择。
  • 治疗早期监测血浆EBV DNA拷贝数变化有助于预测缓解。
  • PD-L1表达状态不宜单独用于筛选获益人群。

局限性

  • 单臂设计,缺乏随机对照。
  • 生物标志物分析为探索性,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chemotherapy. PATIENTS AND METHODS: In this single-arm, multicenter phase II study, patients with RM-NPC received 3 mg/kg toripalimab once every 2 weeks via intravenous infusion until confirmed disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR). The secondary end points included safety, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS: Among all 190 patients, the ORR was 20.5% with median DOR 12.8 months, median PFS 1.9 months, and median OS 17.4 months. Among 92 patients who failed at least two lines of systemic chemotherapy, the ORR was 23.9%. The ORRs were 27.1% and 19.4% in PD-L1+ and PD-L1- patients, respectively (P = .31). Patients with ≥ 50% decrease of plasma Epstein-Barr virus (EBV) DNA copy number on day 28 had significantly better ORR than those with < 50% decrease, 48.3% versus 5.7% (P = .0001). Tumor mutational burden had a median value of 0.95 muts/mega-base in the cohort and had no predictive value for response. Whole-exome sequencing results from 174 patients revealed that the patients with genomic amplification in 11q13 region or ETV6 genomic alterations had poor responses to toripalimab. CONCLUSION: The POLARIS-02 study demonstrated a manageable safety profile and durable clinical response of toripalimab in patients with chemorefractory metastatic NPC. An early decrease in plasma EBV DNA copy number correlated with favorable response.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wang FH, Wei XL, Feng J, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). J Clin Oncol. 2021. PMID: 33492986. doi:10.1200/JCO.20.02712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。